FTH

Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. (FTH) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Profitability (C). The rating has held at C+ for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.6
EV / EBITDA -8.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -53.2%
Price Return 12M 38.9%
Catalyst Signal 0.00
Market Cap $345.0M
TTM Revenue N/A
Price / Sales N/A
ROE -195.3%

Historical Factor Score Progression

Held C+ for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) B- (3.1) C (2.4) C+ (2.7) C+ (2.6) C+ (2.7)
2026-11-05 C+ (2.5) B- (3.1) C (2.4) C+ (2.8) C+ (2.7) C+ (2.7)
2026-10-29 C+ (2.5) B- (2.9) C+ (2.5) C+ (2.6) C+ (2.7) C+ (2.6)
2026-10-22 C+ (2.5) B- (2.9) C (2.5) C+ (2.7) C+ (2.6) C+ (2.6)
2026-10-15 C+ (2.5) B- (2.9) C (2.5) B- (3.0) C+ (2.6) C+ (2.7)
Page 1 of 4